BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment

BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment

Source: 
BioSpace
snippet: 

California-based BioMarin Pharmaceutical released new data today from its previously reported four-year update of the open-label Phase I/II study of valoctocogene roxaparvovec. The investigational gene therapy treatment is designed for patients with severe hemophilia A. The results were presented at the World Federation of Hemophilia (WFH) Virtual Summit by Professor John Pasi, M.B., Ch.B., Ph.D., from Barts and the London School of Medicine and Dentistry and Chief Investigator.